NK92 cells stably transfected with CD16 are efficient against multiple myeloma cells <i>ex vivo</i> and <i>in vivo</i>, especially if combined with daratumumab.

ABSTRACT: Adoptive cell therapy and the use of monoclonal antibodies are two therapeutic modalities implemented in the treatment of multiple myeloma (MM). In this study, we combined the anti-CD38 therapeutic mAb daratumumab with different types of NK cells, leveraging the antibody-dependent cell-mediated cytotoxicity (ADCC) performed by these immune cells. Daratumumab was initially combined with activated and expanded NK cells (eNK), resulting in significant cytotoxic activity against human MM cell lines. As an alternative model to minimize the variability among donors of NK cells, the NK92 cell line was used, which showed greater cytotoxic activity than eNK cells against MM cell lines. However, since NK92 cells lacked CD16 receptor expression, they could not be used in combination with mAbs. To cir

SUBMITTER: Giraldos D 

PROVIDER: S-EPMC12477875 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature